X4 Pharmaceuticals (XFOR) Cost of Revenue (2024 - 2026)

X4 Pharmaceuticals (XFOR) has reported Cost of Revenue for 3 consecutive years, with $1.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 396.01% year-over-year to $1.6 million; the trailing twelve-month figure through Jun 2026 stood at $2.9 million (down 47.41% YoY), and the FY2025 full-year result was $5.8 million, up 622.33% from the prior year.
• Cost of Revenue climbed to $1.6 million in Q2 2026 per XFOR's latest filing, from $598000.0 in the prior quarter.
• Across five years, Cost of Revenue topped out at $4.7 million in Q1 2025 and bottomed at $227000.0 in Q3 2024.
• Historically, Cost of Revenue has averaged $974333.3 across 3 years, with a median of $351000.0 in 2025.
• The widest YoY moves for Cost of Revenue: up 396.01% in 2026, down 87.32% in 2026.
• Over 3 years, Cost of Revenue stood at $302000.0 in 2024, then gained by 20.53% to $364000.0 in 2025, then surged by 344.23% to $1.6 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $1.6 million, $598000.0, and $364000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.